Cold plasma treatment of patient‐derived chronic lymphocytic B‐cell leukemia enhances cytotoxic T‐cell proliferation

Cold physical plasma, a partially ionized gas, has been shown to be effective in treating chronic wounds and cancer. However, there is limited research on plasma exposure of leukemia cell lines, such as chronic lymphocytic leukemia (CLL) and cytotoxic CD8+ T cells. To investigate the potential proim...

Full description

Saved in:
Bibliographic Details
Published in:Plasma processes and polymers 2024-09, Vol.21 (9), p.n/a
Main Authors: Golpour, Monireh, Asgarian‐Omran, Hossein, Akhavan‐Niaki, Haleh, Alimohammadi, Mina, Alizadeh‐Forutan, Maryam, Sohbatzadeh, Farshad, Bekeschus, Sander, Rafiei, Alireza
Format: Article
Language:English
Subjects:
Cold plasmas
Cold treatment
Leukemia
Lymphocytes
plasma jet
plasma medicine
reactive oxygen species
ROS
T lymphocytes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cold physical plasma, a partially ionized gas, has been shown to be effective in treating chronic wounds and cancer. However, there is limited research on plasma exposure of leukemia cell lines, such as chronic lymphocytic leukemia (CLL) and cytotoxic CD8+ T cells. To investigate the potential proimmunogenic effects of plasma‐derived reactive oxygen species, cytotoxic T cells were isolated from CLL patients and healthy volunteers. Extensive cold plasma treatment reduced T‐cell metabolic activity and viability in both diseased and healthy groups. Plasma treatment of cocultures, but not CD8+ T‐cell monocultures, spurred cytotoxic T‐cell proliferation, possibly due to plasma‐enhanced CLL antigen display and plasma‐mediated modulation of immunoregulatory surface molecules. Further studies are needed to understand the mechanisms and clinical relevance of these findings. Cold physical plasma treatment of CD8+ T cells, when cocultured with patient‐derived leukemia cells, potentially supports and increases anticancer T‐cell activity.
ISSN:1612-8850
1612-8869
DOI:10.1002/ppap.202400008